Middle Meningeal Artery Embolization for recurrent chronic subdural hematoma in ToKYo

Middle Meningeal Artery Embolization for recurrent chronic subdural hematoma: a multi-center prospective study in ToKYo - MMAE-TKY

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051516

Enrollment

Registered

2023-08-01

Start date

2023-08-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Chronic Subdural Hematoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have undergone MMAE treatment for recurrent chronic subdural hematoma (symptomatic, refractory, progressive) at participating institutions.

Exclusion criteria

Exclusion criteria: 1. Patients whose modified Rankin Scale was 4 or above prior to the onset of neurological symptoms. 2. Any other instances deemed inappropriate for study by the overseeing physician.

Design outcomes

Primary

Measure	Time frame
A second recurrence within 90 days following embolization for recurrent chronic subdural hematoma	—

Countries

Japan

Contacts

Public ContactTakahiro Ota

Tokyo Metropolitan Tama Medical Center Department of Neurosurgery

takaota@tama-mail.jp042-323-5111

Outcome results